A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer
To access this article, please choose from the options below
PII: S0305-7372(05)00050-2
doi:10.1016/j.ctrv.2005.03.009
© 2005 Elsevier Ltd. All rights reserved.
